MERCK & CO. INC. (MRK)
US58933Y1055 - Common Stock
MERCK & CO. INC.
NYSE:MRK (4/19/2024, 7:04:59 PM)
After market: 125.4 -0.38 (-0.3%)125.78
+0.55 (+0.44%)
Company Profile
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company is headquartered in Kenilworth, New Jersey and currently employs 69,000 full-time employees. The firm offers health solutions through its prescription medicines, including biological therapies, vaccines and animal health products. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products. Its human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription for the treatment of human disorders. The company sells human health pharmaceutical products to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Company’s Animal Health segment develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products as well as health management solutions for the prevention, treatment and control of disease in all livestock and companion animal species. The Company’s product MK-7240 is used for the treatment of immune-mediated diseases including ulcerative colitis, and Crohn’s disease.
Company Info
MERCK & CO. INC.
2000 Galloping Hill Road
Kenilworth NEW JERSEY 07033
P: 19087404000
CEO: Kenneth C. Frazier
Employees: 69000
Website: https://www.merck.com/
MRK News
22 hours ago - Merck Canada Inc.Health Canada Approves KEYTRUDA® as a first-line treatment for adult patients with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with fluoropyrimidine- and/CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced that Health Canada has granted approval of KEYTRUDA® (pembrolizumab),...
3 days ago - InvestorPlaceComing FDA Approvals Could Send These 3 Drug Stocks SoaringWhen it comes to drug stocks, FDA approval can bring years or even decades of steady, high-margin revenue.
4 days ago - InvestorPlace3 Dow Stocks to Buy Now: Q2 EditionAlthough the idea of Dow stocks to buy now is patently boring, that could be a positive attribute amid the current backdrop.
5 days ago - The Motley FoolBetter Growth Play: Merck or The Vanguard Growth Index Fund?Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund?
6 days ago - The Motley FoolMerck Paid $208 Million to Stop Its Drugs From Working. Here's Why That's Bullish.Being able to stop a drug's unwanted effects could lead to a larger market share.
8 days ago - The Motley Fool1 New Green Flag for Moderna and Merck StockThere's a new reason to believe that their joint projects are going well.
MRK Twits
Here you can normally see the latest stock twits on MRK, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
